
KU 59403
CAS No. 845932-30-1
KU 59403 ( —— )
产品货号. M33395 CAS No. 845932-30-1
KU 59403 是 ATM 的一个有效抑制剂,其对 ATM、DNA-PK 和 PI3K 的 IC50 值分别为 3 nM、9.1 μM 和 10 μM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
25MG | ¥6897 | 有现货 |
![]() ![]() |
50MG | ¥9149 | 有现货 |
![]() ![]() |
100MG | ¥13541 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称KU 59403
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述KU 59403 是 ATM 的一个有效抑制剂,其对 ATM、DNA-PK 和 PI3K 的 IC50 值分别为 3 nM、9.1 μM 和 10 μM。
-
产品描述KU 59403 is a potent ATM inhibitor, with IC50 values of 3 nM, 9.1 μM and 10 μM for ATM, DNA-PK and PI3K, respectively.
-
体外实验KU 59403 (1 μM) enhances VP-16 (1 μM) cytotoxicity to a similar extent in HCT116 and HCT116-N7 cells, and in the p53 mutant SW620 cells and human breast cancer cell line, MDAMB-231, sensitisation is 11.9±4.7 and 3.8±1.8-fold respectively. Inhibition of IR-induced ATM activity by KU 59403 (1 μM) is approximately 50% in MDA-MB231 cells and >50% in HCT116 cells that have low ATM expression and activity.Cell Viability Assay Cell Line:LoVo, HCT116 and SW620 (human colon cancer), and U2OS (human osteosarcoma) and MDA-MB-231 (human breast cancer) cells.Concentration:1 μM.Incubation Time:16 hours.Result:Had at least 1000 times greater specificity for ATM over other members of the PI3K family tested.Enhanced camptothecin cytotoxicity in both cell lines with greater enhancement being observed in the LoVo compared to the SW620 cells. Significantly enhanced the cytotoxicity of fixed concentrations of VP-16 (0.1 and 1 μM) or NSC 123127 (10 or 100 nM) in these cell lines, with greater enhancement of VP-16 in SW620 cells and of NSC 123127 in LoVo cells.
-
体内实验KU59403 with a single daily dose of 12.5 mg/kg causes a significant sensitization.Increasing the dose of KU59403 to 25 mg/kg given twice daily results in the greatest chemo-sensitisation with a 3-fold increase in BMY-40481-induced tumour growth delay in both SW620 and HCT116-N7 xenografts, in the absence of a significantly increased toxicity.Animal Model:CD-1 nude mice implanted with SW620 or HCT116-N7 human cancer cell lines at 1×107 cells per animal s.c. (n=5 per group).Dosage:6, 12.5 and 25 mg/kg.Administration:I.P. twice daily (0 and 4 hours) and 12.5 mg/kg once daily.Result:Treatment with BMY-40481 alone causes a modest tumour growth delay of 4 days (time to RTV4=10.5 days). This delay is extended to 8.5 days when given with KU 59403 at 12.5 mg/kg i.p. twice daily for 5 days and 11.5 days (time to RTV4=18 days) when given with KU 59403 at 25 mg/kg i.p. twice daily for 5 days.
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点ATM/ATR
-
受体ATM/ATR
-
研究领域——
-
适应症——
化学信息
-
CAS Number845932-30-1
-
分子量564.72
-
分子式C29H32N4O4S2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 10 mg/mL (17.71 mM; 超声助溶 (<60°C)
-
SMILESCN1CCN(CCC(=O)Nc2ccc3Sc4c(Sc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)CC1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Batey MA, et al. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther. 2013 Jun;12(6):959-67.?
产品手册




关联产品
-
Camonsertib
Camonsertib (RP-3500) 是一种口服有效的,选择性 ATR 激酶抑制剂 (ATRi),在生化试验中的 IC50 为 1.00 nM。Camonsertib 对 ATR 的选择性是 mTOR 的 30 倍 (IC50=120 nM),是 ATM、DNA-PK 和 PI3Kα 激酶的 > 2,000 倍。Camonsertib 具有有效的抗肿瘤活性。
-
BAY-1895344
BAY-1895344 是一种有效的、选择性的、口服活性的 ATR 抑制剂,具有低纳摩尔效力;有效抑制广谱人类肿瘤细胞系的增殖,平均 IC50 为 78 nM;抑制羟基脲诱导的 H2AX 磷酸化,在多种异种移植模型中单一疗法中表现出强大的体内抗肿瘤功效。
-
Ro 90-7501
Ro 90-7501 是一种淀粉样 β42 (Aβ42) 原纤维组装抑制剂,可降低 Aβ42 诱导的细胞毒性 (EC50 为 2 μM)。Ro 90-7501 抑制 ATM 磷酸化和 DNA 修复。RO 90-7501选择性增强 TLR3和 RLR 配体诱导的 IFN-β 基因表达和抗病毒反应。Ro 90-7501 还以 TPR 依赖性方式抑制蛋白磷酸酶 5 (PP5),并对宫颈癌细胞具有显着的放射增敏作用。